The ASCO Post Podcast
Harborside
Subscribe
News and views from the world of clinical oncology and hematology.
Available episodes
Newest first
Oldest first
2 days ago
Reports From the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer was held recently in Phoenix, Arizona. On this episode, we’ll hear from two researchers who presented data at the meeting on ovarian and cervical cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
May 13, 2022
MONALEESA-3: Updated Overall Survival Analysis
On this episode, we’ll be discussing an updated overall survival analysis from the MONALEESA-3 trial presented at the ESMO Breast Cancer Congress 2022. Then, we’ll hear from a researcher about the current state of cancer research and anticipated trends in the field.
*Coverage of stories discussed this week on ascopost.com:*
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
May 6, 2022
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Adult Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
On May 4, the FDA approved fam-trastuzumab deruxtecan-nxki for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. We highlight findings from the DESTINY-Breast03 trial that led to the regular approval, and also hear from Dr. Sara Hurvitz, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, who discussed the trial results with _The ASCO Post_ at the 2021 San Antonio Breast Cancer Symposium.
*Coverage of stories discussed this week on ascopost.com:*
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Apr 27, 2022
More From the AACR Annual Meeting 2022: Future Research Trends
On this episode, we’ll continue our coverage of the American Association for Cancer Research, or AACR, Annual Meeting. We’ll hear from three specialists on the future of cancer research and treatment; the development of novel therapeutic strategies to target DNA damage response; and an overview of the FDA’s accelerated approval program.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 18, 2022
Data From the AACR Annual Meeting 2022
The American Association for Cancer Research, or AACR, Annual Meeting took place from April 8 to 13 in New Orleans. The AACR Annual Meeting brings together the cancer research community to share the latest advances in cancer science and medicine, from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. On this episode of the podcast, we’ll hear from three researchers who presented data at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 4, 2022
Highlights From the NCCN 2022 Annual Conference
The NCCN 2022 Annual Conference took place from March 30 to April 1 as a virtual event. Designed to meet the educational needs of the interprofessional oncology care team, the conference offered more than 30 educational sessions featuring the latest advances and experts in oncology care. On this episode of the podcast, we’ll hear from three speakers who discussed recent advances in cancer care in their respective fields.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 29, 2022
FDA Approvals in Prostate and Endometrial Cancers
In this week’s episode, we are discussing two recent FDA approvals—one for prostate cancer, and the other for endometrial cancer. The radioconjugate lutetium Lu-177 vipivotide tetraxetan was approved for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Pembrolizumab was approved as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair–deficient as determined by an FDA-approved test; eligible patients have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer
FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 18, 2022
FDA Approval in Germline BRCA-Mutated, HER2-Negative, High-Risk Early Breast Cancer
In this week’s episode, we’ll discuss a recent FDA approval in germline _BRCA_-mutated, HER2-negative, high-risk early breast cancer. Then, we’ll hear about the publication of final overall survival results from the MONALEESA-2 trial, which evaluated the efficacy of the addition of ribociclib to letrozole in the first-line treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Mar 11, 2022
First FDA Approval for Neoadjuvant Therapy for Early-Stage Non–Small Cell Lung Cancer
In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the de-escalation of radiation therapy for oropharyngeal cancer.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Neoadjuvant Nivolumab and Platinum Doublet Chemotherapy for Early-Stage NSCLC
Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Mar 4, 2022
Reports From the 2022 Multidisciplinary Head and Neck Cancers Symposium
The 2022 Multidisciplinary Head and Neck Cancers Symposium took place from February 24 to 26 in Phoenix, Arizona. The meeting provided the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, and scientific breakthroughs in head and neck cancer. On this episode of the podcast, we’ll hear from three authors who presented their research at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 1, 2022
More From the ASCO Genitourinary Cancers Symposium: Data on Bladder Cancer, Prostate Cancer, and Treatment Disparities
In this episode, we’re highlighting three presentations from the ASCO Genitourinary Cancers Symposium, held recently in San Francisco.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Feb 18, 2022
News From the 2022 ASCO Genitourinary Cancers Symposium
The 2022 ASCO Genitourinary Cancers Symposium kicked off this week. On this episode, we’ll hear about two studies presented at the meeting: one, focused on a genetic risk score that may aid in identifying men with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer; and the second, about a trial that tested the efficacy of combination immunotherapy and tyrosine kinase inhibitor therapy for renal cell carcinoma.
*Coverage of stories discussed this week on ascopost.com:*
Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Feb 11, 2022
Efficacy of Adagrasib in Various Gastrointestinal Cancers
In this episode, we’ll review a report on the KRYSTAL-1 trial of adagrasib therapy in various gastrointestinal cancers, and highlight key points from the newly released AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.
*Coverage of stories discussed this week on ascopost.com:*
KRYSTAL-1: Adagrasib Controls Disease in Gastrointestinal Malignancies Beyond Colorectal Cancer
AACR Releases Report on the Impact of COVID-19 on Cancer Research and Patient Care
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Feb 4, 2022
President Biden Relaunches the Cancer Moonshot
This week, we're reviewing a statement issued by the White House earlier this week on the Cancer Moonshot initiative.
*Coverage of stories discussed this week on ascopost.com:*
President Biden Reignites Cancer Moonshot
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jan 28, 2022
FDA Approval in Metastatic Uveal Melanoma
On this episode, we’ll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jan 24, 2022
Highlighted Presentations From the 2022 ASCO Gastrointestinal Cancers Symposium
The 2022 ASCO Gastrointestinal Cancers Symposium took place in San Francisco from January 20 to 22. This week, we’re featuring commentary from the authors involved in two high-impact studies in hepatobiliary cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jan 14, 2022
Relatlimab Plus Nivolumab Improves PFS in Patients With Previously Untreated Metastatic or Unresectable Melanoma
On this episode, we’ll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.
*Coverage of stories discussed this week on ascopost.com:*
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma
Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jan 7, 2022
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.
*Coverage of stories discussed this week on ascopost.com:*
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Study Finds Fully Vaccinated Patients With Cancer and Breakthrough COVID-19 Infection Remain at High Risk for Severe Outcomes
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Dec 17, 2021
Research From the 2021 ASH Annual Meeting & Exposition
The 2021 ASH Annual Meeting & Exposition took place from December 11-14. This week, we’re highlighting two studies featured as late-breaking abstracts at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Dec 11, 2021
Research From the 2021 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium was held from December 7 to 10. On this episode, we’ll hear from three authors of high-impact research that was presented during the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Dec 3, 2021
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Advanced Melanoma
On this episode, we’ll hear about a study that examined the impact of the time of day that a patient with advanced melanoma receives an immune checkpoint inhibitor infusion on overall survival. Then, we’ll hear about two recent approvals from the FDA—one in relapsed or refractory multiple myeloma, and one for identification of ovarian cancer lesions during surgery.
*Coverage of stories discussed this week on ascopost.com:*
Impact of Time of Day of Immune Checkpoint Inhibitor Infusion on Overall Survival in Patients With Metastatic Melanoma
FDA Approves Triplet Therapy for Previously Treated Patients With Relapsed or Refractory Multiple Myeloma
FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Nov 19, 2021
SITC 2021: New Data in Immunotherapy
The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. This week, we’ll hear from two researchers who presented data at SITC.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Nov 10, 2021
NCCN 2021 Virtual Congress on Hematologic Malignancies: Round-up
The National Comprehensive Cancer Network’s 2021 Virtual Congress on Hematologic Malignancies took place from October 14 to October 16. The meeting focused on updates to the NCCN Guidelines; new, emerging, and novel therapeutic agents; advances in cancer care; and the practical management of patients with hematologic malignancies. This week, we hear from three presenters who participated in the conference.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Nov 5, 2021
Prostate Cancer Research From the 2021 ASTRO Annual Meeting
This week, we’re reviewing research highlights in prostate cancer that were presented at the 2021 ASTRO Annual Meeting. We’ll hear from three presenting authors on the role of radiotherapy in combination with androgen-deprivation therapy, androgen suppression, and surgery.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 29, 2021
News From the 2021 ASTRO Annual Meeting
The 2021 ASTRO Annual Meeting took place in Chicago from October 24 to October 27. This week, we’re hearing from authors of three late-breaking abstracts. The research focuses on the role of radiotherapy in HPV-associated oropharyngeal cancer, as well as in oligoprogressive lung and breast cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 22, 2021
Oncology Care in the Ongoing COVID-19 Pandemic: Expert Commentary
Recently, Dr. Govind Persad, of the University of Denver Sturm College of Law, wrote an op-ed for _The ASCO Post_ entitled “Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic.”
On this episode of the podcast, Dr. Persad further discusses the challenges that patients with cancer and their physicians face surrounding COVID-19, as well as some possible solutions. As hospitals and providers have coped with those in urgent need of care, the question of how to prioritize cancer treatments has come to the fore.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 15, 2021
FDA Approvals in Breast and Cervical Cancers
This week, the FDA approved new indications for two drugs. The first approval was for abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who are at high risk of disease recurrence and who also have a Ki67 score of 20% or higher. The next day, the agency approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 8, 2021
Lung Cancer Data From the ESMO Congress 2021
This week, we’re hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 27, 2021
ESMO Congress 2021: News in Genitourinary Cancers
This week, we explore more findings presented during the virtual ESMO Congress 2021—specifically, data in genitourinary oncology. We’ll hear from researchers on the efficacy and safety of abiraterone acetate added to different regimens for different types of prostate cancer, as well as patient-reported quality of life with adjuvant pembrolizumab vs placebo for renal cell carcinoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 20, 2021
High-Impact Research From the ESMO Congress 2021
On September 16th, the virtual ESMO Congress 2021 began. This week, we’ll hear from the authors of three influential, late-breaking studies presented at the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 13, 2021
News From the IASLC 2021 World Conference on Lung Cancer
This week, we’re hearing about three abstracts presented during the IASLC 2021 World Conference on Lung Cancer, focusing on clinical trial enrollment during the COVID-19 pandemic, air pollution's role in lung cancer risk, and strategies for reducing barriers and improving cancer care in low-resource areas.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 3, 2021
Withdrawal of Atezolizumab's Indication for Metastatic Triple-Negative Breast Cancer
This week, we’re reviewing the details of Genentech’s decision to withdraw atezolizumab’s indication for metastatic triple-negative breast cancer. We’ll then hear about a systematic review and meta-analysis that provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy.
*Coverage of stories discussed this week on ascopost.com:*
Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Aug 27, 2021
Recent FDA Approvals: dMMR Solid Tumors and von Hippel Lindau–Associated Cancers
This week, we’ll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.
*Coverage of stories discussed this week on ascopost.com:*
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors
FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Aug 23, 2021
Breakthrough COVID-19 Infection in Vaccinated Health-Care Workers
This week, we’ll be discussing a study that examined rates of breakthrough COVID-19 infection in vaccinated health-care workers. Then, we’ll move on to a report that compared the efficacy of different durations of anastrozole treatment in patients with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy.
*Coverage of stories discussed this week on ascopost.com:*
Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Aug 9, 2021
Presentations From the 2021 Pan Pacific Lymphoma Conference
On this episode, we’re hearing from experts presenting data on hematologic malignancies during the 2021 Pan Pacific Lymphoma Conference, which begins on August 9 and concludes on August 13.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jul 30, 2021
Defining Cure in Multiple Myeloma
Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further.
*Coverage of stories discussed this week on ascopost.com:*
Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jul 23, 2021
Recommendations on the Use of Liquid Biopsy for Lung Cancer
On this episode, we’re reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We’ll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer.
*Coverage of stories discussed this week on ascopost.com:*
Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC
SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jul 16, 2021
FDA Approval in Urothelial Cancer, Plus Mechanisms of Acquired Resistance in KRAS G12C–Mutant Cancers
This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with _KRAS _G12C–mutant cancers.
*Coverage of stories discussed this week on ascopost.com:*
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jul 9, 2021
Five- vs 2-Year Course of Zoledronate for Patients With Early Breast Cancer
This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival.
*Coverage of stories discussed this week on ascopost.com:*
Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Jul 2, 2021
News From the EHA 2021 Virtual Congress: Multiple Myeloma, Myelofibrosis, and Leukemia
This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jun 25, 2021
News in Genitourinary Cancers From the 2021 ASCO Annual Meeting
This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jun 18, 2021
Lung Cancer Data From the 2021 ASCO Annual Meeting
This week, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jun 11, 2021
2021 ASCO Annual Meeting: Reports on Kidney, Esophageal, and Cervical Cancers
This week, we’re continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jun 4, 2021
100th Episode: Reports From the 2021 ASCO Annual Meeting in Breast, Prostate, and Lung Cancers
This week marks our 100th episode of the podcast! We launched at the start of the 2019 ASCO Annual Meeting, and this week, we’re reporting major findings from the 2021 Annual Meeting, including adjuvant therapy for patients with BRCA-mutated breast cancer, LuPSMA for metastatic prostate cancer, and an update on CodeBreak100, the trial that led to the recent FDA approval of sotorasib for KRAS G12C–mutated non–small cell lung cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
May 28, 2021
USPSTF Recommendation on Colorectal Cancer Screening Beginning at Age 45
This week, we’re discussing the recent U.S. Preventive Services Task Force, or USPSTF, recommendation on colorectal cancer screening beginning at 45. Then, we’ll hear about a doublet regimen that produced durable responses in patients with advanced head and neck cancer. Lastly, we’ll hear about a study being presented during the ASCO Annual Meeting about a novel immunotherapy combination for advanced melanoma.
*Coverage of stories discussed this week on ascopost.com:*
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Pembrolizumab Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
May 21, 2021
2021 ASCO Annual Meeting: Data From a Premeeting Presscast
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed . On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of Medicaid expansion on long-term survival for patients with cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
May 14, 2021
Comparison of Adjuvant Trastuzumab Courses for Early HER2-Positive Breast Cancer
We’ll start off hearing about an analysis of 9 weeks vs 1 year of adjuvant trastuzumab for patients with early HER2-positive breast cancer. Then, we’ll review a retrospective cohort study that aimed to quantify cancer screening deficits in the United States associated with the COVID-19 pandemic.
*Coverage of stories discussed this week on ascopost.com:*
Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer
The COVID-19 Pandemic and Cancer Screening Deficits in the United States
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
May 7, 2021
Dr. John and Liza Marshall on Their New Book Off Our Chests: A Candid Tour Through the World of Cancer
This week, _The ASCO Post_ sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor.
The Marshalls are the coauthors of a new book entitled_ Off Our Chests: A Candid Tour Through the World of Cancer_, published this week by IdeaPress Publishing and named one of the “10 Books to Read in May 2021” by _The Washington Post_.
Together, they discuss the impact of Liza’s breast cancer diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their book has an important message.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 30, 2021
Intensified Preoperative Therapy for Patients With Newly Diagnosed Locally Advanced Rectal Cancer
This week, we’ll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we’ll talk about the FDA’s approval of a new agent for advanced endometrial cancer.
*Coverage of stories discussed this week on ascopost.com:*
Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 26, 2021
Short-Term Safety of the COVID-19 Vaccine in Patients With Cancer Receiving Immunotherapy
This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We’ll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy
First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Apr 19, 2021
More News From the AACR Annual Meeting: Cancer Biology, Brain Metastases, and Diet
On this week’s podcast, we’re continuing our coverage of the 2021 AACR Annual Meeting. We’ll hear from researchers on the role of cancer biology in treatment paradigms; novel strategies in the care of patients with brain metastases; and the influence of diet on cancer development and response to therapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 12, 2021
News From the AACR Annual Meeting: NSCLC, Lymphoma, and Uveal Melanoma
The 2021 AACR Annual Meeting launched week 1 of a two-week program on April 10 featuring plenary sessions and major scientific symposia. Week 2 will take place in May. In this week’s podcast, The ASCO Post speaks with faculty at AACR’s annual meeting who presented clinical research in non–small cell lung cancer, non-Hodgkin lymphoma, and uveal melanoma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Apr 2, 2021
Differences in Disease Between Younger and Older Women With Breast Cancer
This week, we’ll be discussing a recent presentation that parsed out differences in disease seen in younger vs older women with breast cancer. We’ll also hear about an update to the NCCN Guidelines for triple-negative breast cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 26, 2021
More From SGO: News in Ovarian and Cervical Cancers
This week, we’re again discussing findings presented during the Society of Gynecologic Oncology’s (SGO) Virtual 2021 Annual Meeting on Women’s Cancer. We’re hearing from three presenting authors on a number of topics, including maintenance olaparib for newly diagnosed advanced ovarian cancer; maintenance niraparib for platinum-sensitive ovarian cancer; and methods for reducing radiotherapy toxicity in patients with cervical cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 19, 2021
News From the Society of Gynecologic Oncology’s 2021 Annual Meeting on Women’s Cancer
The Society of Gynecologic Oncology’s virtual 2021 Annual Meeting on Women’s Cancer is taking place from March 19 to 25. This week, we’re hearing about findings presented at the meeting in endometrial and ovarian cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Mar 12, 2021
Increase in Breast Cancer Diagnoses After Pandemic-Related Screening Interruptions
More than a year into the COVID-19 pandemic, researchers are beginning to examine the effects of the virus in the larger health-care sphere. This week, we’ll review a report on an observed increase of breast cancer diagnoses in Italy after pandemic-related screening interruptions. We’ll also discuss two FDA approvals that occurred over the past week for lymphoma and kidney cancer.
*Coverage of stories discussed this week on ascopost.com:*
Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic
FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Mar 8, 2021
Recent Regulatory Decisions in Multiple Myeloma and Lung Cancer
This week, we’re discussing recent regulatory decisions, ranging from FDA approvals in multiple myeloma and non–small cell lung cancer to the withdrawal of a widely used drug’s indication for small cell lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma*
*
FDA Approves Lorlatinib for Metastatic _ALK_-Positive NSCLC
Pembrolizumab's Indication in Small Cell Lung Cancer Is Withdrawn
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Feb 25, 2021
Genitourinary Cancers Symposium: Immunotherapy for RCC, Neoadjuvant Therapy for Bladder Cancer
This week, we’re continuing our coverage of results presented at the 2021 Genitourinary Cancers Symposium, focusing on research findings in renal cell carcinoma and bladder cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Feb 19, 2021
Genitourinary Cancers Symposium: Bladder and Kidney Cancers Research
The 2021 Genitourinary Cancers Symposium took place virtually from February 11 to 13. This week, we’re hearing from three authors of novel research in bladder and kidney cancers.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Feb 12, 2021
IASLC WCLC 2020: Research in Mesothelioma, Small Cell Lung Cancer, and Drug Development
This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Feb 5, 2021
IASLC WCLC 2020: Updates From the ADAURA Trial and More
This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jan 29, 2021
Prevalence of KRAS G12C Mutations Across Different Populations
This week, we’ll discuss the findings of a study that examined the prevalence of _KRAS_ G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
*Coverage of stories discussed this week on ascopost.com:*
Prevalence of _KRAS _G12C Somatic Mutations by Cancer Type, Race, and Sex
FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic _ALK_-Positive ALCL
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jan 22, 2021
More From GI21: Findings in Gastric Cancer, Cholangiocarcinoma, and Pancreatic Cancer
This week, we’re back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in _IDH1_-mutated cholangiocarcinoma, and the POLO trial in _BRCA_-mutated pancreatic cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jan 15, 2021
Findings From the 2021 Gastrointestinal Cancers Symposium
The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We’re discussing findings from the meeting with three study authors.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Jan 8, 2021
IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Patients With Advanced Colon Cancer
This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
*Coverage of stories discussed this week on ascopost.com:*
Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Dec 18, 2020
News From the 2020 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we’re featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Dec 11, 2020
More News From ASH: Whole-Genome Sequencing of Myeloproliferative Neoplasms and More
This week, we’ll focus further on studies presented at the 2020 ASH Annual Meeting & Exposition, including findings on the use of whole-genome sequencing to trace the origins of a blood cancer; stem cell transplant for older patients with myelodysplastic syndromes; and a triplet therapy for relapsed and refractory multiple myeloma.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Dec 6, 2020
News From the 2020 ASH Annual Meeting & Exposition
The 2020 ASH Annual Meeting & Exposition, held in a virtual format this year, begins today. We’re featuring three studies on the podcast this week from the meeting.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Nov 20, 2020
COVID-19: Infection Rate Among Patients Undergoing Anticancer Therapy and Its Effect on Cancer Clinical Trials
As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second explores how the ongoing pandemic is affecting the way patients with cancer choose to participate in clinical trials.
*Coverage of stories discussed this week on ascopost.com:*
Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Nov 13, 2020
Immune-Related Adverse Events and Survival Outcomes in NSCLC
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung cancer screening and treatment.
*Coverage of stories discussed this week on ascopost.com:*
Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
To listen to more podcasts from ASCO, visit asco.org/podcasts.
*
*
playlist_add
Nov 6, 2020
Prostate Cancer Highlights From the 2020 ASTRO Annual Meeting
This week, we're focusing on high-impact research in prostate cancer presented during the virtual 2020 ASTRO Annual Meeting.
The studies included a focus on GnRH receptor antagonist therapy; imaging-based guidance for radiotherapy intensification; and methods of radiotherapy boosts.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 30, 2020
2020 ASTRO Annual Meeting: High-Impact Research
This week, we’ll be featuring discussions of two late-breaking abstracts presented during the virtual 2020 American Society for Radiation Oncology, or ASTRO, Annual Meeting. The first focuses on the role of imaging to plan treatment with radiotherapy in patients with prostate cancer. The second discusses strategies to manage the pain of spinal metastases.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 23, 2020
Recent FDA Approvals in Leukemia and Lymphoma
This week, we’ll focus on two recent approvals from the U.S. Food and Drug Administration in patients with leukemia and lymphoma, respectively.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Venetoclax Combination Regimen for Certain Adult Patients With AML
FDA Extends the Approval of Pembrolizumab for Patients With Classical Hodgkin Lymphoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 16, 2020
First-Line Atezolizumab vs Chemotherapy for PD-L1–Positive Metastatic NSCLC
This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.
*Coverage of stories discussed this week on ascopost.com:*
First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110
Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 9, 2020
Breast Cancer News From the ESMO Virtual Congress 2020
This week, we’ll be featuring our last disease-specific roundup from the ESMO Virtual Congress 2020. We’ll hear from three experts on their findings in breast cancer, focusing on results from two IMpassion trials as well as the efficacy of a novel antibody-drug conjugate in triple-negative disease, and a telehealth program for patients receiving chemotherapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Oct 2, 2020
Lung Cancer Reports From the ESMO Virtual Congress 2020
This week, we’ll be reviewing results from several reports on lung cancer presented during the ESMO Virtual Congress 2020. The findings focus on the use of radiotherapy, biomarkers, targeted treatments, and immunotherapy.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 25, 2020
ESMO Virtual Congress 2020: Spotlight on Genitourinary Cancers
This week, we’re hearing about three reports on genitourinary cancers presented at ESMO Virtual Congress 2020. We’ll hear directly from the researchers about first-line treatment for metastatic renal cell carcinoma, as well as the long-term results of a doublet therapy for men with advanced hormone-naive prostate cancer.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 19, 2020
ESMO Virtual Congress 2020: Findings in Breast and Head and Neck Cancers
This weekend, the ESMO Virtual Congress 2020 is underway, and we’re sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the event.
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 11, 2020
Veliparib Plus Carboplatin/Paclitaxel in BRCA-Mutated, HER2-Negative Advanced Breast Cancer
We’ll discuss the efficacy of a triplet combination therapy in _BRCA_-mutated, HER2-negative advanced breast cancer. Then, we’ll move on to a report that detailed multiorgan immunotherapy-related adverse events in patients treated with atezolizumab. Last, we’ll review the FDA’s approval of the RET-targeted therapy pralsetinib in patients with metastatic RET fusion–positive non–small cell lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With _BRCA_-Mutated Advanced Breast Cancer: BROCADE3 Trial
New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials
FDA Approves Pralsetinib for Metastatic _RET_ Fusion–Positive NSCLC
To listen to more podcasts from ASCO, visit asco.org/podcasts.
playlist_add
Sep 4, 2020
From the Archive: Insights on Young-Onset Colorectal Cancer
Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in _Black Panther, Marshall_, and _Get on Up_, was only 43 when he died from colon cancer. This week, we’ll go back in _The ASCO Post Podcast_ archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults.
playlist_add
Aug 28, 2020
Highlights From the IASLC Virtual Presidential Symposium
This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.
playlist_add
Aug 21, 2020
Decline in Non–Small Cell Lung Cancer Mortality From 2013 to 2016
We’ll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we’ll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.
*Coverage of stories discussed this week on ascopost.com:*
Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
playlist_add
Aug 14, 2020
Pathologic Complete Response in the I-SPY2 Trial
This week, we’ll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we’ll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we’ll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.
*Coverage of stories discussed this week on ascopost.com:*
Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer
Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease
playlist_add
Aug 7, 2020
New Guidelines on Cervical Cancer Screening
This week, we’ll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we’ll discuss the FDA’s approval of a triplet therapy for advanced melanoma. Lastly, we’ll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.
*Coverage of stories discussed this week on ascopost.com:*
American Cancer Society Updates Guideline for Cervical Cancer Screening
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced _BRAF _V600–Mutated Melanoma
playlist_add
Jul 31, 2020
Comparison of Two Combination Treatments in Localized Pancreatic Cancer
This week, we’ll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we’ll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we’ll review the FDA’s recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.
*Coverage of stories discussed this week on ascopost.com:*
First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
playlist_add
Jul 24, 2020
Cabozantinib for Patients With Advanced Bladder Cancer
This week, we’ll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we’ll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we’ll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.
Coverage of stories discussed this week on ascopost.com:
Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma
Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted*
*
playlist_add
Jul 17, 2020
Lenvatinib Plus Pembrolizumab for Patients With Advanced Gastric Cancer
This week, we’ll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We’ll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we’ll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.
*Coverage of stories discussed this week on ascopost.com:*
Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer
USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer
FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
playlist_add
Jul 10, 2020
Spotlight on Two Breast Cancer Studies From the ASCO20 Virtual Scientific Program
This week, we’ll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.
playlist_add
Jul 2, 2020
Multiple Myeloma Research From the ASCO20 Virtual Scientific Program
This week, we’ll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.
playlist_add
Jun 26, 2020
COVID-19 Research From the ASCO20 Virtual Scientific Program
With this week bringing record highs of COVID-19 infection across the nation, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.
playlist_add
Jun 19, 2020
Findings in Prostate Cancer From the ASCO20 Virtual Scientific Program
We're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program.
playlist_add
Jun 12, 2020
Plenary Research From the ASCO20 Virtual Scientific Program: Part 2
This week, we’ll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program.
playlist_add
Jun 5, 2020
Plenary Research From the ASCO20 Virtual Scientific Program: Part 1
This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.
playlist_add
May 29, 2020
Coagulation Issues in Patients With COVID-19: Part 2
In part 2 of our conversation with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy, Dr. Abutalib outlines methods of treatment and prevention for coagulation issues in patients with COVID-19, and summarizes the hematologic consequences of the virus.
playlist_add
May 21, 2020
Coagulation Issues in Patients With COVID-19: Part 1
This week, we spoke with Dr. Syed Abutalib, Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and Co-Editor of Advances in Cell and Gene Therapy. Dr. Abutalib outlines recent data on coagulation issues seen in patients with COVID-19.
playlist_add
May 12, 2020
Highlights From the AACR Virtual Annual Meeting
This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with _BRAF_ V600-mutated melanoma; and a paper on trends in the locations of tobacco and vape shops.
playlist_add
May 5, 2020
Does Ibrutinib Offer a Protective Effect Against Pulmonary Injury in Patients With COVID-19?
This week, we’ll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we’ll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline_ BRCA_-mutated breast cancer. Lastly, we’ll review the FDA’s approval of niraparib for patients with advanced ovarian cancer.
*Coverage of stories discussed this week on ascopost.com:*
Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19
AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial
FDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer
*
*
playlist_add
Apr 28, 2020
Recent FDA Oncology/Hematology Approvals
The U.S. Food and Drug Administration (FDA) had a very busy 10 or so days, so this week, we’ll go over five recent oncology and hematology approvals the Agency issued, in bladder cancer, breast cancer, bile duct cancer, and leukemia.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Mitomycin for Low-Grade Upper Tract Urothelial Cancer
FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an_ FGFR2_ Rearrangement or Fusion
FDA Approves Ibrutinib/Rituximab for CLL/SLL
FDA Approves Sacituzumab Govitecan-hziy for Patients With Previously Treated Metastatic Triple-Negative Breast Cancer
playlist_add
Apr 17, 2020
Characteristics and Outcomes of Patients With Both COVID-19 and Cancer
To begin this week, we’ll discuss a report that focused on the characteristics and outcomes of patients with both COVID-19 and cancer in Wuhan, China. Next, we’ll turn to a paper on the efficacy of stereotactic ablative radiotherapy in men with oligometastatic prostate cancer. Lastly, we’ll talk about the FDA’s approval of encorafenib plus cetuximab in patients with _BRAF_ V600E–mutated colorectal cancer.
*Coverage of stories discussed this week on ascopost.com:*
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial
FDA Approves Encorafenib/Cetuximab for_ BRAF _V600E–Mutated Metastatic Colorectal Cancer
playlist_add
Apr 13, 2020
Report on the ASH COVID-19 Registry for Malignant Hematology
We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative’s Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we’ll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week’s episode, we’ll go over the FDA’s approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.
*Coverage of stories discussed this week on ascopost.com:*
ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19
Does Breastfeeding Affect Invasive Ovarian Cancer Risk?
FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes
playlist_add
Apr 6, 2020
End-of-Trial Findings From CLEOPATRA
This week, we’ll start with a report on end-of-trial findings with a triplet combination treatment for HER2-positive metastatic breast cancer. Then, we’ll hear from the director of a comprehensive cancer center on how her institution is handling the coronavirus outbreak. Lastly, we’ll discuss the FDA’s approval of durvalumab in small cell lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
End-of-Study Results From CLEOPATRA: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
FDA Approves Durvalumab as Part of a First-Line Combination Regimen for Extensive-Stage SCLC
playlist_add
Mar 27, 2020
Cancer Care Amid the COVID-19 Pandemic
To start off this week, we’ll discuss a report from physicians in Washington state about how they’re handling cancer care currently in their institutions amid the COVID-19 pandemic. We’ll then hear from Dr. Giuseppe Curigliano, who spoke with The ASCO Post from his office in Milan about how Italy is addressing the needs of patients with cancer. Lastly, we’ll go over a paper about the reintroduction of a combination regimen when disease progresses after upfront treatment in patients with colorectal cancer.
*Coverage of stories discussed this week on ascopost.com:*
Managing Cancer Care During the COVID-19 Pandemic
Reintroduction of FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
playlist_add
Mar 19, 2020
Coronavirus, Patients With Cancer, and the Preparedness of the Institutions That Care for Them
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
*Coverage of stories discussed this week on ascopost.com:*
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
playlist_add
Mar 13, 2020
Pulmonary Pathology of the Novel Coronavirus in Two Patients With Lung Cancer
We’ll begin this week by discussing an article that described the pulmonary pathology of the novel coronavirus, or COVID-19, which was found coincidentally in two patients undergoing surgery for lung cancer. We’ll also update you as to upcoming oncology meetings that have been cancelled due to concerns about the virus.
We’ll then turn to a report that found adjuvant gemcitabine/platinum chemotherapy was associated with improved disease-free survival vs surveillance in patients with locally advanced urothelial carcinoma of the upper urinary tract.
Finally, we’ll hear a summary of an important talk given at the recent ASCO-SITC Immuno-Oncology Symposium.
*Coverage of stories discussed this week on ascopost.com:*
Pulmonary Pathology of Early COVID-19 Pneumonia Identified Retrospectively in Two Patients With Lung Cancer
Adjuvant Gemcitabine/Platinum-Based Chemotherapy vs Surveillance for Upper Tract Urothelial Carcinoma: POUT Trial
playlist_add
Mar 6, 2020
News From the 2020 Multidisciplinary Head and Neck Cancers Symposium
This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Isatuximab-irfc–Based Triplet Regimen for Patients With Relapsed or Refractory Multiple Myeloma*
*
playlist_add
Feb 27, 2020
News From the Genitourinary Cancers Symposium
This week, we’ll be reviewing data from three influential abstracts presented at the recent 2020 Genitourinary Cancers Symposium in San Francisco—one on a novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha inhibitor for heavily pretreated patients with metastatic clear cell renal cell carcinoma; the second, on whether pembrolizumab in combination with the antibody-drug conjugate enfortumab vedotin may be an alternative option for platinum-ineligible patients with locally advanced or metastatic urothelial carcinoma; and the third, on treatment with pembrolizumab plus enzalutamide after disease progression on enzalutamide in patients with castration-resistant prostate cancer.
playlist_add
Feb 21, 2020
Pembrolizumab Plus Chemotherapy in HER2-Negative Breast Cancer
We’ll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we’ll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we’ll review a long list of treatments for which the FDA recently granted Priority Review.
*Coverage of stories discussed this week on ascopost.com:*
Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer
Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer
playlist_add
Feb 14, 2020
H pylori Infection and Gastric Cancer Risk
First, we’ll discuss a Korean trial that looked at the role of _H pylori_ infection and gastric cancer risk. Next, we’ll turn to a modeling study that examined HPV vaccination and cervical cancer incidence in low-income and lower–middle-income countries. Last this week, we’ll look at data presented at the ASCO-SITC Clinical Immuno-Oncology Symposium on reducing the risk for immune checkpoint inhibitor–associated colitis.
*Coverage of stories discussed this week on ascopost.com:*
Does Treating Individuals for _H pylori _Infection Reduce Gastric Cancer Risk in Those With a Family History of the Disease?
Modeling the Impact of HPV Vaccination and Cervical Screening on Cervical Cancer Elimination in Low-Income and Lower-Middle–Income Countries
playlist_add
Feb 6, 2020
BEACON CRC: Patient-Reported Quality of Life Results
This week, we’ll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium: Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in _BRAF _V600E–mutated colorectal cancer; Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers; and Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.
*Coverage of stories discussed this week on ascopost.com:*
2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC
2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test
playlist_add
Jan 30, 2020
News From the Gastrointestinal Cancers Symposium
The 2020 Gastrointestinal Cancers Symposium took place last weekend, and today, we’ll take a deeper dive into findings in pancreatic cancer and colorectal cancer. We’ll also review the FDA approval of tazemetostat in epithelioid sarcoma.
*Coverage of stories discussed this week on ascopost.com:*
‘Unprecedented’ Responses to Cisplatin/Gemcitabine in_ BRCA_-Mutated Advanced Pancreatic Cancer
FDA Approves Tazemetostat for Epithelioid Sarcoma
playlist_add
Jan 24, 2020
Elevations in Cancer Incidence Among Responders to the WTC Site After the September 11 Attacks
We’ll begin with a study that focused on elevations in cancer incidence among responders to the World Trade Center site after the September 11, 2001 terrorist attacks. We’ll then turn to an analysis evaluating the effect of proton pump inhibitor use on decreased cognitive functioning among breast cancer survivors. Lastly, we’ll look at a trial that compared detection and grading of prostate cancer with a novel artificial intelligence system vs seasoned experts.
*Coverage of stories discussed this week on ascopost.com:*
Cancer Incidence in World Trade Center Responders to the September 11 Attacks
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
playlist_add
Jan 17, 2020
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian cancer? Finally, we’ll cover two recent approvals from the FDA, for patients with bladder cancer and gastrointestinal stromal tumors, respectively.
*Coverage of stories discussed this week on ascopost.com:*
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
FDA Approves PD-1 Inhibitor for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
FDA Approves Avapritinib for the Treatment of _PDGFRA_-Mutated Gastrointestinal Stromal Tumor
playlist_add
Jan 10, 2020
Recent Approvals From the FDA
The FDA certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast cancer; enfortumab vedotin-ejfv for previously treated advanced urothelial cancer; enzalutamide for metastatic castration-sensitive prostate cancer; and atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic nonsquamous non–small cell lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
FDA Approves Olaparib for Patients With Germline_ BRCA_-Mutated Metastatic Pancreatic Cancer
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
FDA Approves Enzalutamide for Patients With Metastatic Castration-Sensitive Prost…
playlist_add
Dec 19, 2019
News From the San Antonio Breast Cancer Symposium
In this episode, we’ll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.
playlist_add
Dec 13, 2019
Plenary Presentations From the 2019 ASH Annual Meeting & Exposition
On this episode, we hear from the authors of three high-impact abstracts presented at the 2019 ASH Annual Meeting & Exposition. The first paper investigated immunotherapy vs standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia; the second focused on the efficacy of oral azacitidine for acute myeloid leukemia; and the third looked at a triplet regimen for relapsed or refractory multiple myeloma.
playlist_add
Dec 5, 2019
Sequence of Therapies for Metastatic Castration-Resistant Prostate Cancer
We’ll start with a trial focused on the sequence of therapies for metastatic, castration-resistant prostate cancer. Then, we’ll move on to an abstract presented at a recent American Heart Association meeting about the link between increased cardiovascular disease risk and increased cancer risk. Lastly, we’ll give you an update about the latest step in the confirmation process for Dr. Stephen Hahn, the oncologist nominated to be the next FDA Commissioner.
*Coverage of stories discussed this week on ascopost.com:*
Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Cardiovascular Disease Risk May Be Associated With Cancer Risk
playlist_add
Nov 27, 2019
Reports From the ESMO Asia Congress 2019
This week, we summarize two studies presented at the recent ESMO Asia Congress—one on a novel combination therapy for unresectable liver cancer, and the second on the activity of a Chinese-manufactured trastuzumab biosimilar. We’ll also discuss last week’s FDA approval of acalabrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
*Coverage of stories discussed this week on ascopost.com:*
ESMO Asia 2019: Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis
playlist_add
Nov 22, 2019
Nivolumab Plus Bevacizumab for Relapsed Ovarian Cancer
According to findings from a phase II trial, the combination of nivolumab and bevacizumab has shown activity in relapsed ovarian cancer—we discuss those findings reported in_ JAMA Oncology_. Next, we’ll move on to a session from CHEST 2019 which outlined palliation techniques that may be of use to oncologists and pulmonologists in treating patients with end-stage lung cancer. Finally, we’ll discuss two recent FDA drug approvals for patients with hematologic disorders.
*Coverage of stories discussed this week on ascopost.com:*
Nivolumab Plus Bevacizumab in Relapsed Ovarian Cancer
What Is the Best Palliation for End-Stage Lung Cancer?
FDA Grants Accelerated Approval to Zanubrutinib for Pretreated Mantle Cell Lymphoma
FDA Approves Luspatercept-aamt for Anemia in Patients With Beta Thalassemia
playlist_add
Nov 15, 2019
ADMIRAL Trial of Gilteritinib vs Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia
The ADMIRAL trial evaluated gilteritinib vs salvage chemotherapy in _FLT3_-mutated acute myeloid leukemia—we'll discuss recently reported overall survival results from _The New England Journal of Medicine._ Then, we’ll move onto findings from a pooled analysis of the relationship between lung cancer risk and high fiber and yogurt consumption. Last, we’ll talk about a recent restructuring of a key office within the FDA.
Coverage of stories discussed this week on ascopost.com:
ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory _FLT3_-Mutated AML
Dietary Fiber, Yogurt Consumption, and Lung Cancer Risk
FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases
playlist_add
Nov 8, 2019
Addition of Durvalumab to Etoposide Plus Platinum Chemotherapy for Extensive-Stage SCLC
This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.
*Coverage of stories discussed this week on ascopost.com:*
CASPIAN Trial: Addition of Durvalumab to Platinum/Etoposide for First-Line Treatment of Extensive-Stage SCLC
Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years Old
American College of Physicians Issues Guidance on Colorectal Cancer Screening for Average-Risk, Asymptomatic Adults Aged 50 to 75 Years
FDA Approves Pegfilgrastim Biosimilar
FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
FDA Approves Daratumumab Combination for Transplant…
playlist_add
Oct 31, 2019
Gastrointestinal Cancer Research From ESMO 2019
This week, we discuss two studies in gastrointestinal cancers presented at this year’s European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in patients with locally advanced pancreatic cancer. Next, we’ll discuss the ClarIDHy study, which examined treatment with ivosidenib in patients with advanced cholangiocarcinoma and an IDH1 mutation. We’ll hear from the lead authors of each of these studies, and we’ll also hear a discussion about the use of cabozantinib in advanced hepatocellular carcinoma, with Dr. Tim Meyer and Dr. Lorenza Rimassa, co-investigators for the CELESTIAL trial.
*Coverage of stories discussed this week on ascopost.com:*
ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer
ESMO 2019: Ivosidenib in _IDH1_-Mu…
playlist_add
Oct 24, 2019
News in Genitourinary Cancers From ESMO 2019
This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on docetaxel and the alternative androgen signaling–targeted inhibitor. The IMvigor130 trial focused on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.
*Coverage of stories discussed this week on ascopost.com:*
ESMO 2019: Cabazitaxel vs Abiraterone or Enzalutamide in Previously Treated Metastatic Castration-Resistant Prostate Cancer
ESMO 2019: IMvigor130: Addition of Atezolizumab to Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma
playlist_add
Oct 17, 2019
Selected Breast Cancer Abstracts From ESMO 2019
This week, we’ll be discussing selected breast cancer abstracts presented at the ESMO Congress 2019, including the MONALEESA-3 and MONARCH-2 studies of CDK4/6 inhibitors for advanced breast cancer; the BROCADE 3 trial of veliparib plus carboplatin and paclitaxel in some advanced _BRCA_-mutated breast cancers; and the KATE-2 study of atezolizumab and trastuzumab emtansine in HER2-positive breast cancer.
*Coverage of stories discussed this week on ascopost.com:*
ESMO 2019: BROCADE 3: Veliparib Plus Carboplatin/Paclitaxel in Patients With HER2-Negative, Germline _BRCA_-Mutated Advanced Breast Cancer
playlist_add
Oct 10, 2019
Lung Cancer Research Highlights From ESMO 2019
This week, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial of osimertinib in EGFR-mutated non–small cell lung cancer; the CheckMate 227 of nivolumab plus ipilimumab vs chemotherapy in non–small cell lung cancer with a PD-L1 expression of 1% or more; and the ASCEND-7 trial of ceritinib for ALK-positive non–small cell lung cancer that has spread to the brain.
Coverage of stories discussed this week on ascopost.com:
ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC
ESMO 2019: ASCEND-7: Ceritinib for Patients With ALK-Positive NSCLC Metastatic to the Brain
playlist_add
Oct 4, 2019
News in Ovarian Cancer From ESMO 2019
This week, we review two studies from a Presidential Symposium at ESMO focusing on the efficacy of PARP inhibitors in patients with newly diagnosed ovarian cancer.
*Coverage of stories discussed this week on ascopost.com:*
ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer
playlist_add
Sep 26, 2019
Benefit of Daratumumab Across Populations With Newly Diagnosed Multiple Myeloma
This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the FDA’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer.
*Coverage of stories discussed this week on ascopost.com:*
Tailoring Upfront Daratumumab Treatment for Some Patients With Multiple Myeloma
AACR Disparities: Mortality Rate for Colorectal Cancer Higher for Blacks Than for Whites in Major U.S. Cities
FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
playlist_add
Sep 20, 2019
News From the ASTRO Annual Meeting
This week, we’ll be going over news from the ASTRO Annual Meeting, including an analysis of the effect of long-term hormonal therapy on men with low PSA levels treated with early salvage radiotherapy after radical prostatectomy and an update on the landmark PACIFIC trial in non–small cell lung cancer. We also discuss the launch of Project Orbis, which led to a joint approval from the FDA, the Australian Therapeutic Goods Administration, and Health Canada for lenvatinib in combination with pembrolizumab in the treatment of some patients with advanced endometrial carcinoma.
*Coverage of stories discussed this week on ascopost.com:*
ASTRO 2019: Long-Term Hormone Therapy May Increase Other-Cause Mortality in Men With Prostate Cancer Receiving Early Salvage Radiotherapy
ASTRO 2019: Patterns of Disease Progression in Patients With Unresectable Stage III NSCLC: Analysis of the PACIFIC Trial
FDA Grants Approval to Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer, Announces Proje…
playlist_add
Sep 13, 2019
News From the IASLC World Conference on Lung Cancer and the ASCO Quality Care Symposium
This week, we’ll be discussing findings presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer and the ASCO Quality Care Symposium, including a pooled analysis on 5-year overall survival rates in patients with previously treated non-small cell lung cancer receiving nivolumab vs docetaxel; the effect of out-of-pocket costs of tyrosine kinase inhibitors on survival in patients with lung cancer; and the relationship between participation in a clinical trial and overall survival in patients with advanced lung cancer.
*Coverage of stories discussed this week on ascopost.com:*
WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
2019 Quality Care: Cost of Treatment, Prior Authorization of Treatment Plans May Cause Barriers to Care
2019 Quality Care: Clinical Trial Enrollment May Be Associated With Reduced Mortality in Patients With Metastatic Lung Cancer
playlist_add
Sep 5, 2019
First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma
This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.
*Coverage of stories discussed this week on ascopost.com:*
Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC
Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types
Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students
playlist_add
Aug 30, 2019
Pooled Survival Analysis of Patients With NSCLC Treated With Nivolumab
This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for _BRCA1_ or _BRCA2_ mutations. Lastly, we discuss the recent FDA approval of entrectinib for _NTRK_-fusion cancers and _ROS1_-positive NSCLC.
*Coverage of stories discussed this week on ascopost.com:*
Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC
USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for _BRCA_-Related Cancer
FDA Approves Entrectinib for_ NTRK_-Fusion Cancers, _ROS1_-Positive NSCLC
playlist_add
Aug 22, 2019
USPSTF Recommendation Against Pancreatic Cancer Screening in Asymptomatic Adults
This week, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms. We also talk about the discovery of a germline mutation that has been newly associated with pancreatic cancer. Lastly, we discuss a U.S. Food and Drug Administration review which concluded a common Parkinson’s disease drug does not contribute to the development of prostate cancer.
*Coverage of stories discussed this week on ascopost.com:*
USPSTF Recommendation on Screening for Pancreatic Cancer in Asymptomatic Adults
Germline _RABL3_ Mutation May Increase Risk of Pancreatic Cancer Development
FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone
playlist_add
Aug 16, 2019
Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL
This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.
*Coverage of stories discussed this week on ascopost.com:*
Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL
Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival
CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries
playlist_add
Aug 9, 2019
Erdafitinib for FGFR-Altered Advanced Urothelial Carcinoma
This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an _FGFR_ alteration.
We also talk about a report from the World Health Organization on tobacco use worldwide.
Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor.
*Coverage of stories discussed this week on ascopost.com:*
Erdafitinib in _FGFR_-Altered Advanced Urothelial Carcinoma
WHO Releases Report on the Global Tobacco Epidemic
FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor
playlist_add
Aug 1, 2019
Overall Survival in MONALEESA-7
This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer.
We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer.
Lastly, we present three recent approvals and regulatory communications from the FDA.
*Coverage of stories discussed this week on ascopost.com:*
Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer
Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer
FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions
FDA Requests Manufacturer Recall of Some Textured Breast Implants
FDA Approves Pembrolizumab f…
playlist_add
Jul 26, 2019
Rates of Early-Onset Colorectal Cancer
This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults.
In addition, Dr. Kimmie Ng, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults.
Then, we turn to a report on the relationship between androgen-deprivation therapy and rates of Alzheimer disease and dementia in elderly patients with prostate cancer.
*Coverage of stories discussed this week on ascopost.com:*
Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends
Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients
playlist_add
Jul 19, 2019
Long-Term Results From the National Lung Screening Trial
This week, we discuss long-term results from an extended analysis of the National Lung Screening Trial, and Dr. James Mulshine of Rush University offers his thoughts on these findings.
We also review a report on radioactive iodine treatment for hyperthyroidism and long-term risk of death from solid cancers.
*Coverage of stories discussed this week on ascopost.com:*
Extended Follow-up From the National Lung Screening Trial Reported
Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?
playlist_add
Jul 11, 2019
ESMO World GI: Findings From the BEACON CRC Trial and More
We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.
*Coverage of stories discussed this week on ascopost.com:*
BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in _BRAF _V600E–Mutated Metastatic Colorectal Cancer
REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer
Chronic Pain in U.S. Cancer Survivors
playlist_add
Jul 3, 2019
ICML 2019: Role of Liquid Biopsy in Lymphoma
In this episode, _The ASCO Post's _Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma.
Later in the podcast, we discuss findings from the PHARE trial on adjuvant trastuzumab dosing in HER2-positive breast cancer and we report two recent approvals by the FDA.
*Coverage of stories discussed this week on ascopost.com:*
Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer
FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma
FDA Approves Bev…
playlist_add
Jun 27, 2019
CASSIOPEIA Trial in Multiple Myeloma
In this episode, we discuss news from the Annual Congress of the European Hematology Association in multiple myeloma, catch up on a study presented at ASCO on gastric cancer, and review a recently published paper on prostate cancer development in World Trade Center first responders.
*Coverage of stories discussed this week on ascopost.com:*
EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma
Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders
playlist_add
Jun 20, 2019
2019 ASCO: Resection of Liver Metastases
In this episode, we discuss more news from the ASCO Annual Meeting, including findings from a study with relevance to surgical oncology, a summary of a study in HER2-positive breast cancer, and a third study on discrimination among hem/onc fellows. We also discuss two FDA approvals which took place in the last week.
*Coverage of stories discussed this week on ascopost.com:*
Discrimination, Gender Bias in Oncology Training and Professional Meetings
FDA Approves New Trastuzumab Biosimilar
FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies
playlist_add
Jun 13, 2019
2019 ASCO: Pancreatic, Urothelial, and Cervical Cancers
In this episode, we discuss more news from the ASCO Annual Meeting, sharing interviews with experts on studies in pancreatic, urothelial, and cervical cancers. We’ll also tell you about a couple of new drug approvals announced this week by the FDA.
playlist_add
Jun 6, 2019
Selected Studies From the 2019 ASCO Annual Meeting
In this debut episode of _The ASCO Post Podcast_, experts in breast, prostate, and lung cancers and multiple myeloma provide clinical insights about selected studies presented at the recent ASCO Annual Meeting, plus news from the FDA.
To learn more, visit ascopost.com/podcasts.
playlist_add
May 26, 2019
Coming Soon: The ASCO Post Podcast
For nearly a decade, The ASCO Post has been bringing you news about clinical advancements in oncology and hematology. Now, this award-winning coverage comes to you in a new format.
To learn more, visit ascopost.com/podcasts.
playlist_add